慢性心力衰竭患者应用美托洛尔缓释片的临床观察

Effect of extended-release metoprolol in patients with chronic heart failure

目的评价β受体阻滞剂琥珀酸美托洛尔控缓释片在慢性心力衰竭患者中的疗效。方法83例慢性心力衰竭患者随机分为美托洛尔缓释片组(A组)或美托洛尔普通片组(B组),在心力衰竭标准治疗基础上,加用美托洛尔缓释片或美托洛尔普通片,逐步滴定至靶剂量,治疗12周,比较两组平均心率和因不良反应而停药的患者比例。结果治疗后两组患者平均心率分别为(67.5±16)次和(69.4±12)次,P=0.041,因各种不良反应而停用的患者比例数分别为9.3%和12.5%,其中A组患者因心力衰竭而入院治疗的危险比B组下降2.9%。结论慢性心力衰竭患者可较好的耐受美托洛尔缓释片,不良反应少。

Objective The objective of the current study was to examine the efficacy and tolerability of the β-blocker extended-release metoprolol in patients with chronic heart failure(CHF).Methods 83 patients with CHF stabilized on optimum standard therapy were randomized to extended-release metoprolol(A group)or immediate-release metoprolol(B group)in a double-blind trial.Metoprolol were titrated to the target dosage,compared the average heart rate of two groups and the adverse events leading to discontinuation after 12 weeks treatments.Results Adverse events leading to discontinuation were 9.3% vs 12.5% respectively,compared with immediate-release metoprolol,extended-release metoprolol produced 2.9% decreased in rehospital rate.Conclusion Patients with CHF have a good tolerability with extended-release metoprolol,with much less adverse events leading to discontinuation.